Determination of anti-CCP antibodies in patients with suspected rheumatoid arthritis: Does it help to predict the diagnosis before referral to a rheumatologist? [1]

Annals of the Rheumatic Diseases

Volumn 64, Issue 10, 2005, Pages 1516-1517

  Gao, I K ^a   Haas Wohrle A ^a   Mueller, K G ^b   Lorenz, H M ^b   Fiehn, C ^b,c  

^a Rheumatology Practice   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Centre for Rheumatic Diseases Baden Baden   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ANTIBODY DETECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; LETTER; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; BLOOD; IMMUNOLOGY; PATIENT REFERRAL;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; PEPTIDES, CYCLIC; REFERRAL AND CONSULTATION;

EID: 27744548020     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.035444     Document Type: Letter

References (11)

1. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42:677-80.
2. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
3. Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chales G, Le Henaff C, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2003;30:2535-9.
4. Zeng X, Ai M, Tian X, Gan X, Shi Y, Song Q, et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003;30:1451-5.
5. Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
6. van Goalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
7. Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, Crespo J, Pena M, Rodriguez-Valverde V, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004;43:655-7.
8. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
9. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Nicolaisen C, Rekvig OP, Nossent HC. Diagnostic value of anti-CCP antibodies in unselected rheumatologic patients [abstract]. Ann Rheum Dis 2004;63(suppl):191.